Virginia G Kaklamani

List of Publications by Year
in descending order

44 papers	3,667 citations	279798 23 h-index	330143 37 g-index
48 all docs	48 docs citations	48 times ranked	5656 citing authors

#	Article	IF	Citations
1	A Coalaâ€Tâ€Cannabis Survey Study of breast cancer patients' use of cannabis before, during, and after treatment. Cancer, 2022, 128, 160-168.	4.1	27
2	Reply to the siren's song of anonymous webâ€based sampling. Cancer, 2022, 128, 1873-1874.	4.1	0
3	Disparities in Cancer Genetic Testing and Variants of Uncertain Significance in the Hispanic Population of South Texas. JCO Oncology Practice, 2022, 18, e805-e813.	2.9	3
4	Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. Journal of Clinical Oncology, 2022, 40, 3246-3256.	1.6	190
5	Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study. Clinical Cancer Research, 2021, 27, 3061-3068.	7.0	66
6	Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer. Journal of Clinical Oncology, 2021, 39, 1360-1370.	1.6	69
7	Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell, 2021, 39, 1091-1098.e2.	16.8	199
8	Subtype-Guided 18F-FDG PET/CT in Tailoring Axillary Surgery Among Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: A Feasibility Study. Oncologist, 2020, 25, e626-e633.	3.7	12
9	Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. Clinical Cancer Research, 2020, 26, 2704-2710.	7.0	21
10	Everolimus Inhibits the Progression of Ductal Carcinoma In Situ to Invasive Breast Cancer Via Downregulation of MMP9 Expression. Clinical Cancer Research, 2020, 26, 1486-1496.	7.0	16
11	ERÎ±-related chromothripsis enhances concordant gene transcription on chromosome 17q11.1-q24.1 in luminal breast cancer. BMC Medical Genomics, 2020, 13, 69.	1.5	6
12	Evaluating the Effect of a Video Education Curriculum for First Time Breast Cancer Patients: a Prospective RCT Feasibility Study. Journal of Cancer Education, 2019, 34, 1234-1240.	1.3	9
13	EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer. Future Oncology, 2019, 15, 3209-3218.	2.4	43
14	Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. New England Journal of Medicine, 2019, 380, 2395-2405.	27.0	349
15	Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer. Future Oncology, 2019, 15, 1641-1653.	2.4	14
16	Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2â€“ERÎ±â€“GREB1 Transcriptional Axis. Cancer Research, 2018, 78, 671-684.	0.9	80
17	Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. New England Journal of Medicine, 2018, 379, 111-121.	27.0	1,558
18	Toxicity disparities between Hispanics and non-Hispanics enrolled in clinical trials in south Texas.. Journal of Clinical Oncology, 2017, 35, e18089-e18089.	1.6	0

#	Article	IF	Citations
19	Clinical Implications of the Progression-Free Survival Endpoint for Treatment of Hormone Receptor-Positive Advanced Breast Cancer. Oncologist, 2016, 21, 922-930.	3.7	10
20	Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579). Breast Cancer Research and Treatment, 2015, 151, 629-638.	2.5	61
21	BRCA 1/2 gene mutation and gastrointestinal stromal tumours: a potential association. BMJ Case Reports, 2015, 2015, bcr2014208830.	0.5	6
22	Yttrium-90 Radioembolization Stops Progression of Targeted Breast Cancer Liver Metastases after Failed Chemotherapy. Journal of Vascular and Interventional Radiology, 2014, 25, 1523-1532.e2.	0.5	55
23	Adiponectin pathway polymorphisms and risk of breast cancer in African Americans and Hispanics in the Womenâ€™s Health Initiative. Breast Cancer Research and Treatment, 2013, 139, 461-468.	2.5	27
24	Metabolic Syndrome and Triple-Negative Breast Cancer: A New Paradigm. International Journal of Breast Cancer, 2012, 2012, 1-10.	1.2	79
25	Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib. Breast Cancer Research and Treatment, 2012, 132, 833-842.	2.5	30
26	Global experience with ixabepilone in breast cancer. Expert Review of Anticancer Therapy, 2011, 11, 683-692.	2.4	3
27	Polymorphisms of ADIPOQ and ADIPOR1 and prostate cancer risk. Metabolism: Clinical and Experimental, 2011, 60, 1234-1243.	3.4	51
28	The role of the fat mass and obesity associated gene (FTO) in breast cancer risk. BMC Medical Genetics, 2011, 12, 52.	2.1	132
29	Can novel genetic polymorphisms predict response to therapy in acute myeloid leukemia?. Leukemia and Lymphoma, 2010, 51, 1161-1162.	1.3	1
30	Capecitabine: treatment options in metastatic breast cancer. Expert Review of Obstetrics and Gynecology, 2009, 4, 367-376.	0.4	0
31	Variants of the Adiponectin (<emph type="ital">ADIPOQ</emph>) and Adiponectin Receptor 1 (<emph type="ital">ADIPOR1</emph>) Genes and Colorectal Cancer Risk. JAMA - Journal of the American Medical Association, 2008, 300, 1523.	7.4	127
32	Variants of the Adiponectin and Adiponectin Receptor 1 Genes and Breast Cancer Risk. Cancer Research, 2008, 68, 3178-3184.	0.9	104
33	Role of Polymorphisms in Adamantiades-BehÃ§etâ€™s Disease. Journal of Rheumatology, 2008, 35, 2376-2378.	2.0	5
34	Transforming Growth Factor Beta and Breast Cancer. , 2005, 126, 129-156.		10
35	Combined Genetic Assessment of Transforming Growth Factor-Î² Signaling Pathway Variants May Predict Breast Cancer Risk. Cancer Research, 2005, 65, 3454-3461.	0.9	83
36	New targeted therapies in breast cancer. Seminars in Oncology, 2004, 31, 20-25.	2.2	37

#	ARTICLE	IF	CITATIONS
37	No major association between TGFBR1*6A and prostate cancer. BMC Genetics, 2004, 5, 28.	2.7	14
38	Role of TGF-Î² in cancer and the potential for therapy and prevention. Expert Review of Anticancer Therapy, 2004, 4, 649-661.	2.4	47
39	Epirubicin Versus Doxorubicin: Which Is the Anthracycline of Choice for the Treatment of Breast Cancer?. Clinical Breast Cancer, 2003, 4, S26-S33.	2.4	76
40	Role of capecitabine (XelodaÂ®) in breast cancer. Expert Review of Anticancer Therapy, 2003, 3, 137-144.	2.4	23
41	The Effect of Smoking on the Clinical Features of Adamantiades-BehÃ§etâ€™s Disease. , 2003, 528, 323-327.		20
42	Advances in adjuvant chemotherapy for breast cancer: the role of taxanes. Journal of the National Comprehensive Cancer Network: JNCCN, 2003, 1 Suppl 1, S107-18.	4.9	0
43	Breast Cancer Prevention. American Journal of Cancer, 2002, 1, 173-178.	0.4	0
44	Anti-estrogen Therapy and Fertility Preservation in Premenopausal Breast Cancer Patients: a Review. Current Breast Cancer Reports, 0, , 1.	1.0	0